

DIASORIN LAUNCHES 2 NEW TESTS FOR THE QUANTITATIVE DETERMINATION OF BORDETELLA PERTUSSIS ON ITS LIAISON XL PLATFORM

April 14, 2015 - Saluggia (VC) - DiaSorin (FTSE Italia Mid Cap:DIA) is pleased to announce that it has launched 2 new LIAISON tests for the quantitative determination of IgG and IgA antibodies to Bordetella pertussis Toxin, available only on the market outside the US

DiaSorin's new tests are the first fully automated solution on the market, which allows a fast and correct diagnosis of the Bordetella pertussis infection.

Pertussis is a highly contagious bacterial disease of the respiratory tract, commonly known as whooping cough, and it is caused by the bacillus Bordetella pertussis.

It occurs mainly in infants and young children and it is easily transmitted from person to person, mainly through droplets. The first symptoms generally appear 7–10 days after infection and include mild fever, and cough, which, in typical cases, gradually develops into a paroxysmal cough followed by whooping (hence the common name of whooping cough).

In the youngest infants, the paroxysms may be followed by periods of apnoea. Untreated patients may be contagious for three weeks or more following onset of the cough.

Pertussis remains an important cause of infant death worldwide and continues to be a public health concern even in countries with high vaccination coverage. Furthermore, maternal antibodies do not appear to protect neonates from severe pertussis.

According to a research of the Centre for Disease Control in the United States, pertussis cases began increasing gradually in the country during the 1980's and by 2013 more than 28,000 cases were reported nationwide. According to the World Health Organization (WHO), there are 50 million new cases each year, with an estimated death of 300,000 people.

Francesco Colotta, Senior Corporate VP and Chief Medical Officer of DiaSorin, commented: *"Data on widespread cases of Pertussis worldwide show the importance of a prompt and correct diagnosis. To answer the need of the market, DiaSorin introduced the first fully automated solution for Bordetella pertussis Toxin, further*



expanding its Infectious Disease menu and strengthening its position as a Diagnostic Specialist”.

REFERENCE TABLE FOR DIASORIN PRODUCTS

Assay name	Bordetella pertussis Toxin IgA and IgG		
Diagnosis	Quantitative determination of Bordetella pertussis Toxin IgA and IgG		
Business segment	Immunodiagnosics	✓	Molecular Diagnostics
Potential market	€ 3 mln worldwide		
Technology	CLIA	✓	Extraction
	ELISA		Amplification/Detection
	RIA		
Clinical Area	Infectious Diseases	✓	Infectious Diseases
	Hepatitis and Retroviruses		
	Oncology & Endocrinology		
	Bone & Mineral		
	Cardiac Markers		Onco-hematology
	GI Stool Testing		

About DiaSorin

Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD “diagnostics specialist”.

For additional information, please contact:

Riccardo Fava
Investor Relations & Corporate Communication Director
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Margherita Sacerdoti
Investor Relations Specialist
Tel: +39.0161.487456
margherita.sacerdoti@diasorin.it